What question did this study set out to answer?

This research addresses the importance of evaluating both clinical and cost outcomes in the value of information (VOI) framework for tuberculosis diagnostics.

March 8, 2026PharmacoEconomics0 citationsOpen Access

Component Clinical and Cost Outcomes Complementing Value of Information: Case Study of a Tuberculosis Diagnostics Clinical Trial

PPPamela P. Pei LQLivia Qoshe GFGrady Florance

Key Points

This research addresses the importance of evaluating both clinical and cost outcomes in the value of information (VOI) framework for tuberculosis diagnostics.
Conducted a clinical trial focusing on tuberculosis diagnostics.
Analyzed both aggregated net monetary benefit (NMB) and disaggregated clinical outcomes.
Evaluated cost savings alongside clinical effectiveness to inform decision-making.
Identified instances where positive NMB might hide unfavorable clinical outcomes.
Highlighted that aggregated VOI may not fully capture the impacts of diagnostics.
Suggested incorporating detailed outcomes in VOI studies for better prioritization.

Abstract

Though a trial may yield positive NMB in conventional VOI analysis owing to expected cost savings, some clinical outcomes might be unfavorable. To better inform priorities, VOI studies should include disaggregated outcomes alongside aggregated NMB.

AI से पूछें

Bookmark

View Full Paper